[1]陈 达,徐 磊,夏秋月,等.HER2、SALL4、GATA3蛋白在乳腺癌组织中的表达及其与患者临床病理特征和预后相关性研究[J].陕西医学杂志,2025,54(2):272-276.[doi:DOI:10.3969/j.issn.1000-7377.2025.02.027]
　CHEN Da,XU Lei,XIA Qiuyue,et al.Expression of HER2,SALL4 and GATA3 proteins in breast cancer tissues and their correlation with clinical pathological characteristics and prognosis in patients with breast cancer[J].,2025,54(2):272-276.[doi:DOI:10.3969/j.issn.1000-7377.2025.02.027]
点击复制

HER2、SALL4、GATA3蛋白在乳腺癌组织中的表达及其与患者临床病理特征和预后相关性研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年2期
页码:
272-276
栏目:
临床病理
出版日期:
2025-02-05

文章信息/Info

Title:
Expression of HER2,SALL4 and GATA3 proteins in breast cancer tissues and their correlation with clinical pathological characteristics and prognosis in patients with breast cancer
作者:
陈 达; 徐 磊; 夏秋月; 时登娟
(临沂市人民医院病理科,山东 临沂 276100)
Author(s):
CHEN Da; XU Lei; XIA Qiuyue; SHI Dengjuan
(Department of Pathology,Linyi People's Hospital,Linyi 276100,China)
关键词:
乳腺癌;  人类表皮生长因子受体2;  婆罗双树样基因4;  GATA结合蛋白3;  临床病理特征;  预后
Keywords:
Breast cancer;  HER2;  SALL4;  GATA3;  Clinical pathological characteristics;  Prognosis
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2025.02.027
文献标志码:
A
摘要:
目的:探讨乳腺癌组织中人类表皮生长因子受体2(HER2)、婆罗双树样基因4(SALL4)、GATA结合蛋白3(GATA3)蛋白表达及其与患者临床病理特征和预后的相关性。方法:选取乳腺癌患者138例,收集患者癌组织和癌旁正常组织标本。癌组织和癌旁组织中HER2、SALL4、GATA3蛋白表达采用免疫组织化学染色法检测。对患者进行5年随访,行Cox回归分析乳腺癌患者预后的影响因素。结果:与癌旁组织比较,乳腺癌组织中HER2、SALL4蛋白阳性表达率升高,GATA3蛋白阳性表达率降低(均P<0.05)。乳腺癌组织HER2、SALL4、GATA3蛋白阳性表达与患者TNM分期和淋巴结转移有关(均P<0.05)。TNM分期Ⅲ-Ⅳ期、有淋巴结转移、HER2蛋白阳性表达、SALL4蛋白阳性表达、GATA3蛋白阴性表达为乳腺癌患者5年内预后不良的独立影响因素(均P<0.05)。HER2、SALL4蛋白阳性表达患者5年生存率低于阴性患者,GATA3阴性患者5年生存率低于阳性患者(均P<0.05)。结论:乳腺癌组织HER2、SALL4蛋白高表达、GATA3蛋白低表达,且三者与乳腺癌患者淋巴结转移、TNM分期和预后有关。
Abstract:
Objective:To investigate the expression of human epidermal growth factor receptor 2(HER2),spalt-like transcription factor 4(SALL4)and GATA-binding protein 3(GATA3)in breast cancer tissues and their correlation with clinical pathological characteristics and prognosis in patients with breast cancer.Methods:A total of 138 patients with breast cancer were selected,and cancerous and adjacent normal tissue specimens were collected from these patients.Immunohistochemical staining was used to detect the expression of HER2,SALL4,and GATA3 proteins in cancerous and adjacent tissues.A 5-year follow-up was conducted for the patients,and Cox regression analysis was performed to identify the influencing factors on the prognosis of patients with breast cancer.Results:Compared with adjacent tissues,the positive expression rates of HER2 and SALL4 proteins were increased,while the positive expression rate of GATA3 protein was decreased in breast cancer tissues(all P<0.05).The positive expression of HER2,SALL4 and GATA3 proteins in breast cancer tissues was related to the patient's TNM staging and lymph node metastasis(all P<0.05).TNM stage Ⅲ-Ⅳ,lymph node metastasis,positive expression of HER2 and SALL4 protein,and negative expression of GATA3 protein were identified as independent factors affecting the poor prognosis of patients with breast cancer within 5 years(all P<0.05).Patients with positive expression of HER2 and SALL4 proteins had lower 5-year survival rates than those with negative expression,and patients with negative GATA3 had lower 5-year survival rates than those with positive expression(all P<0.05).Conclusion:High expression of HER2 and SALL4 proteins,and low expression of GATA3 protein in breast cancer tissues are associated with lymph node metastasis,TNM staging and prognosis in patients with breast cancer.

参考文献/References:

[1] XU Y,QI Y,LU Z,et al.Navigating precision:The crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive,human epidermal growth factor receptor2-negative early breast cancer[J].Cancer Biol Ther,2024,25(1):2405060.
[2] MO H,ZHANG X,REN L.Analysis of neuroglia and immune cells in the tumor microenvironment of breast cancer brain metastasis[J].Cancer Biol Ther,2024,25(1):2398285.
[3] 张慧峰,李茉,许淑娣,等.拉帕替尼治疗HER2阳性局部晚期乳腺癌临床疗效研究[J].陕西医学杂志,2023,52(5):596-599.
[4] 高宏,周立江,邢向荣,等.柴胡龙骨牡蛎汤加减治疗乳腺癌研究进展[J].陕西中医,2023,44(11):1657-1659.
[5] 张彩虹,张永梅.循环肿瘤DNA检测在乳腺癌早期诊治中的应用进展[J].检验医学与临床,2024,21(22):3417-3421.
[6] 张祥盛.WHO(2012)乳腺肿瘤组织学分类[J].诊断病理学杂志,2012,19(6):477-478.
[7] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609-679.
[8] 雷志鑫,杨海旖,谢浩,等.miRNA在乳腺癌中的研究进展[J].华中农业大学学报,2024,43(5):149-156.
[9] XU K,ZHAO H,ZHOU Y.Commentary:Knowledge mapping of immunotherapy for breast cancer:A bibliometric analysis from 2013-2022[J].Hum Vaccin Immunother,2024,20(1):2360819.
[10] RAZA S,SIDDIQUI J A,SRIVASTAVA A,et al.Autophagy as a therapeutic target in breast tumors:The cancer stem cell perspective[J].Autophagy Rep,2024,3(1):27694127.
[11] 孙雪梅,苗佳贤,卜维航,等.HR阳性乳腺癌新辅助治疗后HER2阴性亚组蛋白水平表达的演变及与临床病理特征的相关性分析[J].临床与实验病理学杂志,2024,40(9):955-960,966.
[12] 郝鑫,胡崇珠,岳瑞雪,等.白蛋白结合型紫杉醇或多西他赛联合卡铂新辅助治疗HER2阳性乳腺癌疗效比较[J].肿瘤防治研究,2024,51(9):779-783.
[13] 周娜,贺艳玲,王倩,等.转移性三阴性乳腺癌原发灶及转移灶ER、PR、HER2、Ki-67表达差异及与预后的关系[J].肿瘤研究与临床,2024,36(8):583-589.
[14] 张团结,巩福玉,卢玉宁,等.奈拉替尼联合卡培他滨治疗HER2阳性晚期乳腺癌患者的临床研究[J].中国临床药理学杂志,2024,40(17):2474-2478.
[15] 洪艳玲.两种鸡尾酒双染法评估乳腺癌HER2表达的应用对比[J].诊断病理学杂志,2024,31(8):811-813.
[16] 王燕艳,王梅,黄琰菁,等.乳腺癌患者婆罗双树样基因4表达情况及PTEN/AKT/mTOR通路对乳腺癌阿霉素耐药性作用研究[J].临床军医杂志,2023,51(9):934-937.
[17] 傅静芬.血清CEA、CA125、CA153联合HER2对乳腺癌的诊断价值[J].中国医学创新,2023,20(8):105-108.
[18] 王茂,代引海,李宏,等.婆罗双树样基因4对乳腺癌细胞阿霉素耐药的影响及其机制探究[J].世界临床药物,2022,43(5):523-532.
[19] 张惠洁,王珏.SALL4、LGR5、NKD1在乳腺癌组织中的表达及意义[J].生物医学工程与临床,2017,21(6):653-659,671.
[20] HSIEH C H,CHANG Y H,LING P Y,et al.Detecting early-stage breast cancer with GATA3-positive circulating tumor cells[J].Taiwan J Obstet Gynecol,2024,63(5):745-749.
[21] 杜琳琳,谢飞,马雪梅.SALL4的促癌功能及治疗意义[J].生物技术进展,2023,13(5):704-711.
[22] 张璐,张瑞,刘俊,等.GATA3通过调控LIFR抑制人乳腺癌细胞的迁移能力[J].医学分子生物学杂志,2024,21(4):293-299.
[23] 詹颖瑛.GATA3、MGB和GCDFP-15在乳腺癌中的病理诊断价值[J].中国实验方剂学杂志,2024,30(14):278.
[24] 陈宝英,韩含,邱璞,等.GATA结合蛋白3和蛋白质精氨酸甲基转移酶5在乳腺癌组织的表达及其临床意义[J].中华实验外科杂志,2023,40(6):1113-1116.
[25] 蔺嘉楠,王立中,余银平,等.GATA结合蛋白3、性别决定相关基因簇2在三阴性乳腺癌中的表达及预后关系[J].诊断病理学杂志,2024,31(2):140-144.

相似文献/References:

[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
　QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(2):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(2):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
　JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(2):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(2):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[7]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
　HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(2):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
[8]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[9]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
　ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(2):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
[10]李福平,王 茂,邱春丽,等.莱菔硫烷联合维生素D对乳腺癌细胞增殖及凋亡的影响[J].陕西医学杂志,2022,51(8):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]
　LI Fuping,WANG Mao,QIU Chunli,et al.Effect of sulforaphane combined with vitamin D on proliferation and apoptosis of breast cancer cells[J].,2022,51(2):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]
[11]王志泉,陈 岩,高 姗,等.超声收缩期峰值血流速度、阻力指数与乳腺癌组织中Survivin、基质金属蛋白酶-11、人类表皮生长因子受体2关系研究[J].陕西医学杂志,2024,(7):910.[doi:DOI:10.3969/j.issn.1000-7377.2024.07.009]
　WANG Zhiquan,CHEN Yan,GAO Shan,et al.Relationship between ultrasonic PSV,RI and Survivin,MMP-11,HER2 in breast cancer tissues[J].,2024,(2):910.[doi:DOI:10.3969/j.issn.1000-7377.2024.07.009]
[12]卜 烨,张晨洁.生存素、人类表皮生长因子受体2、巨囊性病液体蛋白15、 Yes相关蛋白表达对乳腺癌患者术后复发转移的预测价值[J].陕西医学杂志,2025,54(1):127.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.026]
　BU Ye,ZHANG Chenjie.The predictive value of Survivin,HER-2,GCDFP15 and YAP protein expression in postoperative recurrence and metastasis of breast cancer patients[J].,2025,54(2):127.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.026]

备注/Memo

备注/Memo:
[基金项目]山东省卫生健康委员会科研项目(BK2021F0127)
更新日期/Last Update: 2025-02-04